H. Zhang, et al. Biochim. Biophys Acta 1808 (2011) 1832-1842. Y.Y. Zuo, et al. Biochim. Biophys Acta 1778 (2008) 1947-1977.

Y.Y. Zuo, et al. Biophys J 94 (2008) 3549-3564.

Estudio interdisciplinario del surfactante pulmonar

H. Zhang, et al. Biochim. Biophys Acta 1808 (2011) 1832-1842. Y.Y. Zuo, et al. Biochim. Biophys Acta 1778 (2008) 1947-1977.

Y.Y. Zuo, et al. Biophys J 94 (2008) 3549-3564.

Síndrome de dificultad respiratoria

Jobe AH. Neoreviews, ©2006 February;7(2):e95-e106.

Kopelman AE, Matthew OP. Common respiratory disorders of the newborn. Pediatr Rev ©1995;16:209–217 Warren JB and Anderson JM. Neoreviews, ©2009 July;10(7);e351.

Guttentag S and Foster CD. Neoreviews, ©2011 November;12(11);e625.

Jobe AH. Neoreviews, ©2006 February;7(2):e95-e106.

Engle WA. Pediatrics, ©2008 February;121(2);419.

Valls-i-Soler A, et al. Pediatrics ©1998;101;e4.

Fig 1. Schematic representation of the dual-lumen ET-tube used. Note that the

distal end of the secondary lumen is located just at the tip of the main lumen of

the ET-tube. The internal diameter (ID) and the internal cross-sectional area

(a) of the main and secondary lumens are given. The resistance of a size 2.0-

mm ID dual-lumen ET-tube, measured at two different ventilator settings (136

6 3.9 and 132 6 1.1 cm H2O/L/second) were similar to those of a single-lumen

ET-tube of the same size (138 6 2.5 and 148 6 1.6 cm H2O/L/second).

Resistance was measured (PeDs, MAS-PTI, Hatboro, PA) using a lung model

(compliance 5 1.0 mL/cm H2O), and a ventilator (Bourns BP-200, Riverside,

CA) at a rate of 30 cycles/minute at two different settings (PIP/PEEP 5 12/2

and 25/5 cm H2O, and peak inspiratory flow 5 1.0 and 3.5 L/minute).

Tube designed whith secondary lumen for the administration of Surfactant.

Updated Published Online:

March 14, 2012

Principales resultados

Conclusiones

Ya-Chen Wang, Hsing-I. Tseng, San-Nan Yang, Chu-Chong Lu, Jiunn-Ren Wu, Zen-Kong Dai, Jong-Hau Hsu, Hsiu-Lin Chen

Guttentag S and Foster CD. Update in Surfactant Therapy. Neoreviews ©2011 November;12:e625-e634.

Guttentag S and Foster CD. Update in Surfactant Therapy. Neoreviews ©2011 November;12:e625-e634.

Síndrome de aspiración meconial

Principales resultados

La evidencia publicada actualmente de ECA sugiere que la terapia de reemplazo de SP es eficaz para el SAM, sin embargo debido a la limitada cantidad y

calidad de los ensayos que se incluyó en el estudio, más

evidencia de ECA es necesaria para demostrar la eficacia.

Eficacia del tratamiento con

surfactante pulmonar en

neonatos con síndrome de

aspiración meconial: un meta-análisis

Fiori HH, et al. Evaluation of surfactant function at birth determined by the stable microbubble test in term and near term infants with respiratory distress. Eur J Pediatr. ©2004 Aug;163(8):443-8.

J Pediatr ©2011 Nov;159(5):750-4.

Biban P, et al. Exogenous surfactant replacement: how to deliver it? Acta Biomed ©2012;83 Suppl 1:27-32. Dargaville PA. Innovation in Surfactant Therapy I: Surfactant Lavage and Surfactant Administration by Fluid Bolus Using Minimally Invasive Techniques. Neonatology ©2012 Jun;101(4):326-44.

Biban P, et al. Exogenous surfactant replacement: how to deliver it? Acta Biomed ©2012;83 Suppl 1:27-32. Dargaville PA. Innovation in Surfactant Therapy I: Surfactant Lavage and Surfactant Administration by Fluid Bolus Using Minimally Invasive Techniques. Neonatology ©2012 Jun;101(4):326-44. Pillow JJ, Minocchieri S. Innovation in surfactant therapy II: surfactant administration by aerosolization. Neonatology ©2012 Jun;101(4): 337-44.

Biban P, et al. Exogenous surfactant replacement: how to deliver it? Acta Biomed ©2012;83 Suppl 1:27-32. Dargaville PA. Innovation in Surfactant Therapy I: Surfactant Lavage and Surfactant Administration by Fluid Bolus Using Minimally Invasive Techniques. Neonatology ©2012 Jun;101(4):326-44.

Biban P, et al. Exogenous surfactant replacement: how to deliver it? Acta Biomed ©2012;83 Suppl 1:27-32. Dargaville PA. Innovation in Surfactant Therapy I: Surfactant Lavage and Surfactant Administration by Fluid Bolus Using Minimally Invasive Techniques. Neonatology ©2012 Jun;101(4):326-44.

Finer NN, et al. An open label, pilot study of Aerosurf® combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulm Drug Deliv ©2010 Oct;23(5):303-9. Biban P, et al. Exogenous surfactant replacement: how to deliver it? Acta Biomed ©2012;83 Suppl 1:27-32. Pillow JJ, Minocchieri S. Innovation in surfactant therapy II: surfactant administration by aerosolization. Neonatology ©2012 Jun;101(4): 337-44.

Lucinactant for inhalation (AEROSURF) Aerosolized Drug-Device Combination Product for RDS

«Sólo los ignorantes creen que la verdad es definitiva y maciza, cuando apenas es provisoria y gelatinosa.

Hay que buscarla porque anda corriendo de escondite en escondite.

Y pobre del que emprenda en soledad esta cacería».

José Mujica